stockportfolio.pro
Stocks / AXGN vs VERA
AXGN vs VERA
Axogen, Inc. and Vera Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Axogen, Inc. (AXGN) | Vera Therapeutics, Inc. (VERA) | |
|---|---|---|
| Market cap | $2.2B | $2.4B |
| Revenue (latest FY) | $225.21M | $0 |
| Net income (latest FY) | $-15.70M | $-299.62M |
| Revenue growth (5y CAGR) | 14.9% | — |
| Net margin | -7.0% | — |
| Return on equity | -12.2% | -49.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AXGN — free Open VERA — freeFrequently asked questions
Which is bigger, AXGN or VERA?
Vera Therapeutics, Inc. is larger by market capitalization — $2.4B versus $2.2B.
Which grows faster, AXGN or VERA?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.